Vanda Pharmaceuticals 3Q 2026: Revenue $69.82M, Net income ($22.56M), EPS ($0.37) — 10-Q Summary
Vanda Pharmaceuticals reported 3Q 2026 revenue of $69.82M, up 24.1% YoY, with a net loss of $22.56M. Diluted loss per share was $0.37. Nine-month product sales rose 8%, with Fanapt and PONVORY sales increasing, while HETLIOZ declined. The company expects to launch BYSANTI in 4Q 2026 and has ongoing trials for NEREUS and BYSANTI.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that may prompt short‑term price adjustments, especially given the net loss and ongoing clinical programs.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking biotech earnings and pipeline milestones.
What to watch
Future catalysts include FDA approvals for BYSANTI and Phase III data for NEREUS, which could offset short‑term weakness.
Background
The article summarizes Vanda Pharmaceuticals' Q3 2026 10‑Q filing, highlighting revenue, net loss, EPS, and pipeline updates.
Ticker impact
Vanda Pharmaceuticals filed its Q3 2026 10‑Q reporting $69.8M revenue, a 24% YoY increase, but a net loss of $22.6M.
likely downward pressure as market prices in the net loss and EPS miss
Revenue rose, but loss widened slightly and EPS remained negative, suggesting limited upside and potential sell‑off.
Market effects
Biotech earnings season may see mixed reactions; Vanda's results highlight ongoing challenges in specialty pharma.
U.S. biotech sector may see modest volatility.
Limited to investors focused on small‑cap pharma.
Counterpoint
Despite the loss, the 24% revenue growth could signal a turnaround if upcoming product launches succeed.
Key entities
- companyVanda Pharmaceuticals Inc.
U.S. specialty pharmaceutical company.
